FIELD: biochemistry.
SUBSTANCE: there is presented a modified antibody used for conjugation with medicinal substances, which, on C-end of the molecule, contains a cysteine-containing motive, having a structure presented by formula 1, presented in the materials of the application. Also disclosed is a conjugate of the above antibody and medicinal agent and methods for preparing it.
EFFECT: invention extends the range of therapeutic agents.
19 cl, 8 dwg, 1 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MULTISPECIFIC ANTIBODIES, THEREOF ANALOGUES, COMPOSITIONS AND METHODS | 2010 |
|
RU2580038C2 |
| ANTIBODIES WITH CYSTEINE SUBSTITUITIONS AND THEIR CONJUGATES PRODUCED BY GENE ENGINEERING | 2011 |
|
RU2626537C2 |
| RADIOACTIVE ZIRCONIUM- LABELLED ENGINEERED CYSTEINE ANTIBODIES CONJUGATES | 2010 |
|
RU2562862C2 |
| ANTIBODIES WITH CYSTEINE SUBSTITUTIONS OBTAINED BY GENETIC ENGINEERING AND THEIR CONJUGATES | 2011 |
|
RU2755066C2 |
| COVALENTLY LINKED CONJUGATES CHELICAR-ANTIBODY AGAINST CHELICAR AND USE THEREOF | 2014 |
|
RU2694981C2 |
| ANTIBODIES AND ANTIBODY FRAGMENTS FOR SITE-SPECIFIC CONJUGATION | 2016 |
|
RU2757815C2 |
| SITE-SPECIFIC HER2 ANTIBODY-DRUG CONJUGATES | 2016 |
|
RU2745565C2 |
| CONJUGATES OF ANTIBODIES AND DRUGS CHARACTERIZED IN HIGH IN VIVO TOLERANCE | 2018 |
|
RU2764031C2 |
| RECOMBINANT Fab-scFv BASED ON A NEUTRALISING ANTIBODY AGAINST HUMAN BETA-1A INTERFERON AND AN ANTIBODY AGAINST HUMAN ErbB2 RECEPTOR | 2019 |
|
RU2748953C1 |
| MODIFIED EPITOPES FOR AMPLIFYING RESPONSES OF CD4+ T-CELLS | 2013 |
|
RU2724994C2 |
